A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 mg as Compared to Amlodipine/Valsartan 5/40 mg or to Amlodipine 5 mg Once Daily in Elderly Patients With Essential Hypertension Not Adequately Controlled After Four Weeks on Amlodipine 5 mg Once Daily
Phase of Trial: Phase III
Latest Information Update: 03 May 2016
At a glance
- Drugs Amlodipine/valsartan (Primary) ; Amlodipine
- Indications Essential hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 23 Jun 2012 Additional location (Hungary) added as reported by European Clinical Trials Database.
- 03 Jun 2011 Protocal amended.